Abstract: A broad-spectrum vaccine against avian Reovirus is disclosed, which is effective in reducing the infection of avian Reovirus in an avian target. The vaccine comprises antigenic material derived from avian Reovirus of two genotype groups: 1 and 4, as defined herein. This vaccine is effective against all avian Reoviruses, homologous or heterologous to the vaccine, including recent virulent break-through strains.

Abstract: Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise and immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms.

Abstract: Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise an immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms.

Abstract: The present invention is concerned with vaccinating equines against the equine influenza virus (EIV). It has now been found that adequate protection against equine influenza in equines can be achieved when vaccination with a live equine influenza vaccine (prime) is followed by vaccination with an inactivated influenza vaccine (boost), wherein the two shots are given no longer than 8 weeks apart.

Abstract: It has been found that adequate protection against viral infection in equines can be achieved when vaccination with a live viral vaccine (prime) is followed by vaccination with an inactivated vaccine (boost) for the same virus, wherein the two shots are given no longer than 8 weeks apart. The invention therefore provides a method for vaccination of equines against infection with an equine viral pathogen, wherein an animal is first vaccinated with a (prime) vaccine comprising an attenuated form of the pathogen, followed by a vaccination with a (boost) vaccine comprising the same pathogen in inactivated form, and wherein the boost vaccine is administered no longer than eight weeks after the prime vaccine. The method of the invention is especially useful for vaccination against viral infections such as infections with EIV and/or EHV-1/EHV-4.

Abstract: The present invention is concerned with vaccinating equines against the equine influenza virus (EIV). It has now been found that adequate protection against equine influenza in equines can be achieved when vaccination with a live equine influenza vaccine (prime) is followed by vaccination with an inactivated influenza vaccine (boost), wherein the two shots are given no longer than 8 weeks apart. The present invention therefore provides a method for vaccination of animals against equine influenza, wherein an animal is first vaccinated with a (prime) vaccine comprising an attenuated equine influenza virus, followed by a vaccination with a (boost) vaccine comprising an inactivated equine influenza virus, and wherein the boost vaccine is administered no longer than eight weeks after the prime vaccine. Preferably the two shots are given no longer than 8 weeks apart, for example, between 3-6 weeks apart, preferably between 4-6 weeks apart.

Abstract: Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise and immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms.

Abstract: It has been found that adequate protection against viral infection in equines can be achieved when vaccination with a live viral vaccine (prime) is followed by vaccination with an inactivated vaccine (boost) for the same virus, wherein the two shots are given no longer than 8 weeks apart. The invention therefore provides a method for vaccination of equines against infection with an equine viral pathogen, wherein an animal is first vaccinated with a (prime) vaccine comprising an attenuated form of the pathogen, followed by a vaccination with a (boost) vaccine comprising the same pathogen in inactivated form, and wherein the boost vaccine is administered no longer than eight weeks after the prime vaccine. The method of the invention is especially useful for vaccination against viral infections such as infections with EIV and/or EHV-1/EHV-4.